

Cite this: *RSC Med. Chem.*, 2023, 14, 2048

Screening and optimization of phage display cyclic peptides against the WDR5 WBM site†

Lingyu Song,^{ab} Jiawen Cao,^{ab} Lin Chen,^b Zhiyan Du,^b Naixia Zhang,^{ac} Danyan Cao^{*b} and Bing Xiong ^{*abd}

Of the various WD40 family proteins, WDR5 is a particularly important multifunctional adaptor protein that can bind to several protein complexes to regulate gene activation, so it was considered as a promising epigenetic target in anti-cancer drug development. Despite many inhibitors having been discovered directing against the arginine-binding cavity in WDR5 called the WIN site, the side hydrophobic cavity called the WBM site receives rather scant attention. Herein, we aim to obtain novel WBM-targeted peptidic inhibitors with high potency and selectivity. We employed two improved biopanning approaches with a disulfide-constrained cyclic peptide phage library containing 7 randomized residues and identified several peptides with micromole binding activity by docking and binding assay. To further optimize the stability and activity, 9 thiol-reactive chemical linkers were utilized in the cyclization of the candidate peptide DH226027, which had good binding affinity. This study provides an effective method to discover potent peptides targeting protein–protein interactions and highlights a broader perspective of peptide-mimic drugs.

Received 23rd June 2023,
Accepted 12th August 2023

DOI: 10.1039/d3md00288h

rsc.li/medchem

Introduction

Epigenetics is a growing field and has shown encouraging early outcomes in drug discovery. Epigenetic alterations have been found in a variety of human malignancies and are thought to be reversible, making them promising targets for pharmacological agents.¹ The main classes of epigenetic inhibitors studied include histone deacetylase (HDAC) inhibitors,² bromodomain-containing protein 4 (BRD4) inhibitors,³ histone lysine methyltransferase nuclear receptor-binding SET domain protein 2 (NSD2) inhibitors,⁴ DNA-methyltransferase (DNMT) inhibitors,⁵ coactivator-associated arginine methyltransferases 1 (CARM1),⁶ and so on. As a member of the WD40 family protein, WDR5 has many essential biological functions, especially in gene expression regulation, and is considered as a promising epigenetic target

for cancer treatment.⁷ WDR5 participates in many protein complexes, such as the MLL complex,⁸ subunits of the nonspecific lethal (NSL) complex,⁹ nucleosome remodeling and deacetylase (NuRD) complex,¹⁰ Ada2a-containing (ATAC) complex¹¹ and Pax transactivation domain-interacting protein (PTIP) complex.¹² As an important cornerstone of these complexes, WDR5 has two confirmed interacting sites: the WDR5-interacting site (WIN site) and the WDR5-binding motif (WBM site). In the MLL complex, WDR5 interacts with MLL1 and RbBP5 through the WIN site and WBM site, respectively. Since 2010, many inhibitors targeting the WIN site that is located at the top of the central cavity and is surrounded by seven leaf β -propeller motifs¹³ have been developed. Compared to the WIN site, the WBM site is a more superficial hydrophobic cavity and requires aliphatic side chains from hydrophobic residues to stabilize interactions. Four partners have been reported to bind to the WBM site: RbBP5, KANSL2, MYC, and lncRNAs.^{9,14} Among these, RbBP5, KANSL2, and MYC share a similar core sequence named the ‘AAXDV’ motif (X = V, I, or L; A is an acidic amino acid).¹⁵ Besides, Asn225 and Gln289 are the key residues in the WBM binding pocket, responsible for the formation of H-bonds with the interacted proteins. Recently, two series of small molecular inhibitors were reported by Fesik's group,¹⁶ which were developed from the fragment hits harboring a salicylic acid scaffold. The binding affinity of these inhibitors against the WBM site of WDR5 was in the range of 30–100 nM. The

^a Department of College of Pharmacy, University of Chinese Academy of Sciences, 19A Yuquan Road, Beijing 100049, China

^b Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
E-mail: s20-songlingyu@simm.ac.cn, caody@simm.ac.cn, bxiong@simm.ac.cn

^c Department of Analytical Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

^d State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3md00288h>



co-immunoprecipitation assay showed that these compounds could disturb the interaction between WDR5 and c-MYC.¹⁷ Limited to a few numbers and types, we know poorly about the mechanism and effectivity of WBM site inhibitors applied in WDR5-associated cancers. Therefore, new types of WBM inhibitors need to be explored urgently.

The discovery of ligands that selectively bind to a certain target plays a vital role in the area of clinically relevant diagnostics and therapeutics. Since it was first described in 1985,¹⁸ phage display has evolved and been known as a widely used and powerful methodology for the study of target-specific ligands and molecular biology mechanisms.¹⁹ Furthermore, the correct and efficient correlation of phenotypes and genotypes achieved by phage display allows for binder identification in only two or three iterative rounds of phage selection, which endows the technique with advantages of low cost and high efficiency. At present, phage-based genetically encoded libraries have become a major pipeline for finding lead compounds.

Importantly, given their intrinsic nature, large surface area and limited conformational flexibility, cyclic peptides possess numerous advantages, such as low toxicity, high binding affinity, great target specificity, excellent metabolic stability and cell permeability.²⁰ Thus, cyclic peptides have emerged as a potential therapeutic modality for drug discovery and disease treatment over the past few decades, especially against challenging targets such as protein–protein interactions.^{21,22} In this paper, we employed biopanning methods with the disulfide-bridged peptide phage display library (Ph.D.TM-C7C phage library, CX₁X₂X₃X₄X₅X₆X₇C, where X represents any amino acid) to explore new peptidic inhibitors toward the WBM site. In general, disulfide-bridged peptides could lose bioactivity easily *in vivo* by reductions, so disulfide bonds inside selected peptides were further replaced with more stable chemical bonds formed by a series of thiol-reactive chemical linkers. Finally, optimized cyclic peptides with better stability and binding affinity were obtained. This article aims to provide a substantial application of phage display cyclic peptides in the WDR5-WBM site.

Results and discussion

Target proteins prepared for screening

For the subsequent biopanning experiments, we prepared both His-tagged WDR5 and biotinylated WDR5 for the screening corresponding to Ni-NTA magnetic agarose beads and streptavidin magnetic beads, respectively. After purification, 19.6 mg WDR5 protein with His-tag was obtained from 9.35 g cells. From the gel-filtration elution profile, we observed that His-tagged WDR5 protein was eluted at a single peak at 89 mL corresponding to 36.5 kDa. The protein concentration before gel filtration should not be too high; otherwise, a peak at 47 mL corresponding to 70.0 kDa appeared which is confirmed to be the aggregation of WDR5. After SDS-PAGE separation, we detected and verified

the bands of protein migrating around 35.0 kDa (Fig. S1†). As for biotinylated WDR5 obtained with a biotinylation kit, a HABA assay was performed to estimate the biotinylated level of WDR5. The absorbance at 500 nm of HABA/avidin solution was 0.6, and the A500 of HABA/avidin/biotin decreased to 0.2. Then, an online HABA calculator on the ThermoFisher website was used and 3.7 biotin groups per protein molecule were obtained for the biotin ratio of WDR5.

Affinity selection of cyclic peptides specific to the WBM site of WDR5

The Ph.D.TM-C7C phage library of random cyclic peptides with a disulfide constrained loop was applied in the WBM-targeting biopanning. As we disclosed previously,²³ peptides with arginine can easily bind to the WIN site of WDR5. So, a small molecular inhibitor (**WIN-IN-4**; CAS: 2407457-36-5) with sub-nanomole binding activity was employed to block the WIN site before selection. Meanwhile, the inhibitor was added to the wash buffer for additional washing of the WIN binding peptides. On the other hand, the enrichment of selection-related target-unrelated peptides (TUPs) is a major problem for phage library screening, which may contribute to false affinity toward the target and give misleading results. Furthermore, phages binding to magnetic beads may predominate during the solution-biopanning.²⁴ Therefore, affinity selection with two different strategies was designed and carried out (Fig. 1). (A) Subtractive panning: only Ni-NTA magnetic agarose beads were used throughout three rounds of the screening, and the amplified phages were incubated with beads prior to His-tagged WDR5 in the first two cycles to deplete bead binders. Besides, an extremely stringent washing procedure was performed. The concentration of **WIN-IN-4** in the wash buffer was raised from 10 μM and 50 μM, to 100 μM stepwise. (B) Alternant panning: two kinds of magnetic beads were employed alternately in three rounds without depleting, and the WIN site inhibitor was kept at 10 μM in the wash buffer under a moderate washing condition.

After each cycle, the phage titer was tested immediately and recovery efficiency could be obtained (Table S1†). As the results indicated, alternant panning without depleting could decrease the loss of library effectively and fold increase increased obviously after three rounds compared with subtractive panning. Then fortunately, when we picked 33 clones and 124 clones of the third round in the subtractive panning and the alternant panning separately for DNA sequencing, no histidine-rich peptides or ‘HPQ’ tripeptide motifs appeared (Fig. S2†), which were the most recognizable TUPs binding to Ni²⁺ and streptavidin, respectively.^{25–27} And it implied that the two kinds of selection methods worked well. Moreover, the ‘RT’-containing peptides decreased significantly in the proportions of total peptides sequenced although they still existed. The ‘RT’-containing sequences could not be eliminated by blocking the WIN site with a sub-nanomole compound, because the chelation interaction between the WIN site and multivalent-displayed peptides was






Fig. 1 The overview of two different panning strategies. (A) The subtractive panning with Ni-NTA magnetic agarose beads throughout the three rounds. (B) The alternant panning with two kinds of magnetic beads employed alternately.

inevitable. Despite all the precautions, it was impossible to completely avoid TUPs adsorbing non-specifically to plastic polystyrene surfaces. Thus, we utilized SAROTUP, a free online service for scanning, reporting and excluding TUPs,²⁸ to distinguish true binders from false-positive plastic binders

with PSBinder values lower than 0.7 (Tables S2 and S3[†]). In the end, the eligible sequences in the screen are listed in Fig. 2. Among the 35 clones in total, 8 sequences emerged more than once and the frequency of the sequence CGSLDWPHC was the highest, indicating that the favourable fold increase exists in the panning. Besides, the sequence CGEGEADVC containing the WBM site conservative 'DV' motif also appeared among these sequences.

Sequence	Reads (Sanger)	PSBinder (SAROTUP)
CPWQVHRDC	3/33	0.53
CADTNWLV	2/33	0.52
CSSNTVPAC	2/33	0.04
CPWKTHQSC	2/33	0.17
CSEARWMRC	2/33	0.12
CSQAWVYQC	1/33	0.24
CPNQWKSQC	1/33	0.27
CNNLNAILC	1/33	0.08
CFLNVSNA	1/33	0.25
CDMPPTQKC	1/33	0.55
CLPNDHLRC	1/33	0.20

Sequence	Reads (Sanger)	PSBinder (SAROTUP)
CGSLDWPHC	5/124	0.69
GMTPNPTTC	2/124	0.35
CDARGGLRC	2/124	0.37
CRALPFNTC	1/124	0.34
CRDKPSNVC	1/124	0.21
CGTNP1KKC	1/124	0.27
CGSNTTVEC	1/124	0.57
CSSNTVPAC	1/124	0.04
CVSTATNGC	1/124	0.39
CNSLNWFVC	1/124	0.30
CSKKNPSWC	1/124	0.25
CYGLSNSRC	1/124	0.40
CGEGEADVC	1/124	0.50
CLNVSSPTC	1/124	0.10
CNNPAGPWC	1/124	0.19
CEPRSLANC	1/124	0.10
CNWRLSNYC	1/124	0.18
CMNEDKFHC	1/124	0.53
CVNSMTYPC	1/124	0.04
C1NINLPKSC	1/124	0.12
CFPNVYHAC	1/124	0.24
CSRSMMMAC	1/124	0.34
CHMYHNATC	1/124	0.00
CHLTHQASC	1/124	0.00

Fig. 2 Partial picked sequences deduced from the third round. (A) 11 sequences from the subtractive panning with Ni-NTA magnetic agarose beads. (B) 24 sequences from the alternant panning with two kinds of magnetic beads.

Docking study and binding affinity assay of sequenced peptides

Molecular docking is a powerful computation tool in drug discovery. Several docking programs have been available for protein-peptide complexes, such as AutoDock CrankPep (ADCP), GalaxyPepDock, MDockPeP, HPEPDOCK, *etc.* A comprehensive evaluation of fourteen docking programs on protein-peptide complexes was reported,²⁹ which shows that ADCP achieves the best predictions and reaches high level success rates in local docking. ADCP has been shown to reliably dock peptides of up to 20 amino acids in length and cyclic peptides with disulfide bonds. We conducted docking study with ADCP after these screens. 35 sequences among the potential binders were picked and prepared by PyMOL for docking (Tables S2 and S3[†]). The highest affinity in the docking results of each sequence was compared, and peptides with an affinity value lower than -21.0 were selected for solid-phase peptide synthesis (SPPS). Finally, 7 cyclic peptides with a single disulfide bridge were synthesized and tested for binding affinity against WDR5 by HTRF assay (Table 1). To



Table 1 The binding affinity of 7 selected peptide sequences derived from the third round of panning

Peptide sequence	Affinity (ADCP) (kcal mol ⁻¹)	HTRF assay IC ₅₀ (μM)
Subtractive panning with Ni-NTA magnetic agarose beads		
DH226015-CADTNWLVC	-22.7	65
D210012-CPNQWKSYS	-22.0	>100
D210014-CSQAWWYQC	-22.7	30
DH226016-CFLNVSNA	-21.1	>100
Alternant panning with two kinds of magnetic beads		
DH210901-CGSLDWPHC	-22.8	25
^a DH226027-CNSLNWFWC	-22.2	2.2
DH226028-CGEGEADVC	-22.0	>100

^a Sequence of the candidate peptide.

our surprise, sequence CNSLNWFWC (DH226027) derived from scoring calculation showed the best binding activity with an EC₅₀ of 2.2 μM, so it could be a candidate peptide for the following structural optimization and modification.

Binding mechanism between DH226027 and WDR5 indicated by ADCP and NMR experiments

After docking, ten ranked PDB files appeared as results and one of the PDB file was chosen to show the binding interactions between DH226027 and WDR5 (Fig. 3A). The data revealed that DH226027 employed both its backbone and side chain atoms when binding to WDR5, forming predominantly hydrogen bonds and cation-π stacking interactions. Six intermolecular hydrogen bonds were formed between N2 of DH226027 and K227, and Y228 of WDR5, between S3 of DH226027 and N225, and K227 of WDR5, and between W8 of DH226027 and K272, and Q289 of WDR5. Formation of cation-π stacking interactions was observed between W6 of DH226027 and P224 of WDR5.

In order to map the interacting sites of the peptide DH226027 in WDR5, [¹H, ¹⁵N] HSQC NMR titration experiments were performed. The residues with their chemical shifts perturbed and attenuated significantly upon the addition of DH226027 in WDR5 were identified as follows: A47, V48, S49, S50, I90, S91, W95, D107, F133, C134, F149, V174, S175, Y191, C195, L209, F219, L230, A232, T233, L234, D235, Y243, K245, E258, K259, Y260, F266, K272, W273, S276, T301, I305, and T307 for DH226027 (Fig. 3B). Compared with the key residues of WDR5-binding regions in the literature,¹³ the perturbed residues in WDR5 upon the binding of DH226027, particularly F266, K272, and W273, localized to the WBM site region. Therefore, the above results demonstrated that the peptide DH226027 could be chosen as a candidate ligand targeting the WBM site in WDR5.

Cyclization of the candidate peptide with different chemical linkers

Disulfide-bridged peptides can be converted to linear peptides *in vivo* by reducing intramolecular disulfide bonds





Fig. 3 (A) The binding interactions between WDR5 and DH226027 in the molecular docking model. The peptide DH226027 and the key residues of WDR5-binding regions are presented as pink and cyan sticks, respectively. Hydrogen bonds and cation-π stacking interactions are represented as yellow and green dashes, respectively. (B) Superposition of the ¹H-¹⁵N-HSQC spectra of ¹⁵N-labeled WDR5 with (blue) and without (red) DH226027.

into free sulfhydryl groups, and the instability severely restricted their intracellular applicability. In order to stabilize the bioactive conformation and improve the binding affinity of the candidate peptide DH226027, one of the promising modification strategies was cysteine alkylation.^{30–32} The key of this method is the identification of optimal linkers. In our work, cyclization was performed with a synthesized linear peptide DH226027-L (H-CNSLNWFWC-NH₂, Fig. S3†), and different chemical linkers were selected and experimentally tested in order to obtain stabilized cyclic peptides with high binding affinity. Hoping to get a cyclic peptide whose chain length is short and close to that of a disulfide bond, 9 thiol-reactive crosslinkers commonly used in peptide cyclization were employed, including benzylbromides C1–C3,^{33,34} allylbromides C4 and C9,³⁵ acetone C5,³⁶ maleimide C6,³⁷ pyridine C7,³⁸ and malonamide C8 (Scheme 1).³⁹

As shown in Fig. 4, among reactions conducted with C1, C2, and C3 in which the 1,2-, 1,3- and 1,4-positions of the benzene ring were decorated with bromine groups, linker C3 gave relatively clean formation of the desired products and it was easy to purify. However, cross-linking reactions with linkers C1 and C2 yielded more by-products. For the rest, HPLC analysis indicated that the most efficient





Scheme 1 The cyclization reactions between the peptide DH226027-L and 9 chemical linkers.

macrocyclizations were carried out by C4 and C7, which provided the major peak of cyclization products proved by LC-MS results. Incubation of peptide DH226027-L with C5 gave a new product with a mass of 1294.37 Da that was inconsistent with the expected mass (1226.47 Da). It was likely that linker C5 with high activity had undergone a lot of side reactions. Cyclization with maleimide linker C6 also resulted in an unknown product mixture which was further complicated because of hydrolysis of imide (observed mass = 1462.38 Da, different from the anticipated mass of 1265.44 Da). Additionally, it was worth noting that the intramolecular disulfide bond formation due to oxidation was a major side reaction. Product analysis revealed that the disulfide-bridged peptide was the main product when C8 was added, and the two peaks of alkenyl-bridged and disulfide-bridged cyclic peptides were too close to separate when DH226027-L was treated with C9.

Above all, we employed C3, C4 and C7 as cyclization reagents to create cyclopeptides CYC3, CYC4, and CYC7 respectively with stable chemical bonds simply and cost-effectively. See the ESI† for more details about HPLC chromatograms and LC-MS spectra (Table S4 and Fig. S4–S6†).

After obtaining three modified cyclic peptides, we performed HTRF assay to acquire their binding affinity targeting the WBM region of WDR5 protein *in vitro*. Before testing the selected peptides, HTRF assay had been proven to be reliable because the positive control peptide SV-10, a peptide derived from MYC MbiIIb, had an affinity with an EC_{50} of $1.6 \pm 0.1 \mu\text{M}$ (Fig. S7†) that was comparable with $K_d = 9.3 \pm 1.7 \mu\text{M}$ in the literature.¹⁵ Based on the results (Fig. 5A), we find that cyclic peptide CYC3 (Fig. 5B) has better binding activity with an EC_{50} of $8.1 \pm 0.5 \mu\text{M}$ among all three synthetic peptides. As shown in the figure, all three cyclopeptides have relatively low inhibition at the high concentration, which is due to poor solubility in the aqueous solution.

Furthermore, the stability of cyclic peptides with a disulfide bond or a chemical linker against a reduction environment was studied. Under the reduction conditions, both DH226027 and CYC3 were dissolved in the acidic or neutral methanol buffer with tris(2-carboxyethyl)phosphine (TCEP), and the changes of the peptide structure at different time points were detected by the HPLC system. As shown in Fig. 6, the disulfide bond in the cyclic peptide DH226027 (HPLC peak 1) was broken rapidly and the corresponding linear peptide (HPLC peak 2) was observed in 30 min under pH 3.0 and pH 7.4 conditions. However, under both conditions, chemically modified cyclic peptide CYC3 was pretty stable without any changes after two hours. The results of this experiment supported our hypothesis that cyclization with chemical linkers could improve stability against a reduction environment under acidic and neutral conditions.

Nevertheless, we found CYC3 has similar binding activity to the original DH226027, and could serve as a new stable cyclic peptide for further biological evaluation.

Conclusions

As an important mediator in several protein complexes, WDR5 protein plays a substantial role in anti-cancer drug development. This article focuses on new peptide-mimic inhibitors of the WBM region in WDR5, which have been seldom reported. At first, we established two different screening strategies with a disulfide-based cyclic peptide library (Ph.D.TM-C7C phage library) that could reduce the proportions of TUPs, and obtained a series of specific peptides targeting the WBM binding site. And then, considering sequencing data and molecular docking ADCP energy, the candidate peptide DH226027 which has good binding activity at the μM level was identified and further modified with different cyclization chemistries. Finally, we found a phenyl-bridged cyclic peptide (CYC3) towards the WDR5-WBM pocket. It has better stability and similar binding affinity compared with the original DH226027. In summary, we believe that our selection and optimization strategies work well for developing peptide-mimic inhibitors in the protein-protein interaction areas. Besides, these opportunities and challenges present a strong case for applying widely the phage display technique in drug discovery and peptide therapeutics.

Experimental

Protein expression and purification for biopanning

The WDR5 (residues 23–483) expression strain with His₆-sumo tag at N-terminal was preserved in-house.²³ The 500 mL terrific broth cultures supplemented with $50 \mu\text{g mL}^{-1}$ kanamycin were inoculated with 1/100 saturated *E. coli* bacterial culture for overnight growth at 37 °C until the OD₆₀₀ reached 0.8. The protein was induced at 0.5 mM isopropyl β -D-1-thiogalactopyranoside (IPTG) and cultured at 18 °C for 16 h before harvest. The cells were lysed using an






Fig. 4 HPLC chromatograms of cyclization reactions between linear peptide DH226027-L and chemical linkers C1–C9.






Fig. 5 (A) Binding affinity derived from HTRF assay of three modified cyclic peptides targeting the WDR5-WBM site (the positive control peptide SV-10: EC₅₀ = 1.6 ± 0.1 μM). (B) The structure of cyclic peptide CYC3.




Fig. 6 HPLC chromatograms of the stability experiments. (A) Peptide DH226027 was dissolved in pH 3.0 solution. (B) Peptide DH226027 was dissolved in pH 7.4 solution. (C) Peptide CYC3 was dissolved in pH 3.0 solution. (D) Peptide CYC3 was dissolved in pH 7.4 solution.

ultra-high-pressure cell disruptor (UH-03, Union, China) in the lysis buffer (50 mM HEPES pH 7.5, 250 mM NaCl, 20 mM imidazole, 5% (v/v) glycerol and 5 mM TCEP). After centrifugation with 12 000 rpm at 4 °C for 1 h, the supernatant was loaded onto a Ni Sepharose 6 FF (Cytiva, Danaher Corporation) gravity column. The target protein was eluted with elution buffer (20 mM HEPES pH 7.5, 250 mM NaCl, 250 mM imidazole, 5 mM TCEP, and 5% (v/v) glycerol)

after the washing procedure with several 30–50 mM imidazole containing buffers. The elution was concentrated with 10 000 MWCO Vivaspin® 20 centrifugal concentrators (Cytiva, Danaher corporation) at 4000 g on the centrifuge 5810R (Eppendorf) at 4 °C before loading onto a Hiload 16/600 Superdex® 200 pg column (Cytiva) in the buffer (20 mM HEPES pH 7.5, 250 mM NaCl, 5 mM TCEP). The fractions with an absorption peak around 89 mL were pooled and concentrated to 10 mg mL⁻¹, and then stored in 20% glycerol at -80 °C.

Biotinylation of WDR5 protein

WDR5 was biotinylated for the alternate magnetism phage biopanning with an EZ-Link™ Sulfo-NHS-LC-Biotinylation kit (Thermo Scientific). The protein was buffer-exchanged to amine-free PBS buffer with a single-use desalting column included in the kit. Then, 500 μL of 230 μM WDR5 in the PBS buffer was added to the 230 μL of freshly prepared 10 mM sulfo-NHS-LC-biotin solution. The reaction was incubated on ice for two hours before buffer exchange to remove the excess biotin reagents. Finally, a HABA assay was performed to verify the level of biotin incorporation, and the biotin/mole value of protein was detected after calculating with the HABA online calculator (ThermoFisher Scientific).

Selective biopanning of phage display cyclic peptides

Phage display peptide library Ph.D.TM-C7C (New England Biolabs Inc) was employed for three rounds of biopanning. To obtain specific peptides binding to the WBM site of WDR5, a positive inhibitor (**WIN-IN-4**; CAS: 2407457-36-5) was used to occupy the WIN site of WDR5. Two solution-phase panning strategies with both His-tagged target and biotinylated protein were adopted.

In the subtractive panning, we used Pierce™ Ni-NTA magnetic agarose beads (ThermoFisher Scientific) for all three cycles. 200 μL of 4 μg His-tagged WDR5 protein was incubated with 10 μM **WIN-IN-4** for 1 h at 4 °C in a 2 mL Eppendorf tube coated with the blocking buffer (PBS containing 1% BSA). 10 μL phage library (2 × 10¹³ pfu mL⁻¹) was diluted in the mixture for further incubation with gentle rotation overnight. After washing and coating, 30 μL Ni-NTA magnetic agarose beads were added to the tube for capturing protein and specific phages at room temperature for 1 h. Unbound phages were washed eight times with PBS containing 0.1% Tween-20 and 20 mM imidazole. Two more washes were followed with 10 μM **WIN-IN-4** added in the wash buffer. Then, the bound phages were eluted with the elution buffer (0.2 M glycine-HCl (pH 2.2), 1 mg mL⁻¹ BSA) for 15 min at room temperature. 1 M Tris (pH 9.1) was added immediately to neutralize the elution. The eluate was tested for phage titration after each round and amplified after the first two cycles as described in the manufacturer's protocol. More importantly, the amplified phages should be mixed twice for half an hour with 100 μL coated Ni-NTA magnetic



agarose beads to deplete false-positive TUPs binding directly to beads before next round screening.

The alternant panning is the same as the previous panning, but the magnetic beads were replaced with Pierce™ Streptavidin magnetic beads (ThermoFisher Scientific) to prevent the enrichment of Ni-specific peptides and imidazole was omitted from the wash buffer in the second round. There was no need for the depleting procedure. Moreover, **WIN-IN-4** was added in the mixture for competitive binding behind the incubation between WDR5 protein and the phage library, and 10 μM **WIN-IN-4** was kept in the wash buffer throughout three rounds. In both selection experiments, the amplified phages were calculated to be 2×10^{11} pfu as an input according to the results of titration. Stringency was gradually enhanced by reducing the amount of protein stepwise (4 μg, 2 μg, 0.5 μg) while enhancing the concentration of Tween-20 in the wash buffer (0.1%, 0.3%, 0.5%, respectively).

Sequence analysis of the selected clones

The sequenced clones were acquired from a colony-PCR protocol directly instead of purifying the phage DNA for more convenience. After titer experiments, blue plaques from the titration plates were picked for a PCR reaction. The primers for the PCR reaction were:

Forward C7C-1: 5'-GTCGGCGCAACTATCGGTATC-3';

Reverse C7C-R1: 5'-GCCCTCATAGTTAGCGTAACG-3'.

The PCR reaction mixture has a total volume of 50 μL including 25 μL of 2× Hieff robust PCR master mix (Yeasen, Suzhou), 1 μL of forward and reverse primers each at 0.4 μM, and the blue plaque picked as a template. The PCR reaction was started by initial denaturation (95 °C, 30 s), followed by 30 cycles of denaturation, annealing, and extension (95 °C for 15 s, 53 °C for 15 s and 72 °C for 30 s). All steps were performed on a SimpliAmp Thermal Cycler. The 313 bp PCR products appeared above the 250 bp DNA marker at 1.5% agarose gel. After that, the target fragments were sent to Personalbio, Inc. (Shanghai China) for Sanger sequencing.

Virtual screening with AutoDock CrankPep (ADCP)

The PDB files of cyclic peptides identified from sequencing analysis were prepared with PyMOL. Docking cyclic peptides to the WBM site of WDR5 was performed using ADCP v1.1. The docking box was set to the WBM site using a ligand (MYC MbIIIb peptide) extracted from 4y7r (PDB code). After computing pockets with AutoSite 1.1, four pockets appeared, and all fills were selected to generate the target file. We performed the docking into this box, performed 50 independent searches, allowed each search to consume 2.5 million evaluations, and peptides were cyclic through cysteine option.

Synthesis of the selected peptides with disulfide bonds

A total of 7 disulfide-bridged cyclic peptides were synthesized by DongHeng Biopharm Co., Ltd. (Hangzhou, China). They were prepared by solid-phase peptide synthesis on an Advanced ChemTech 348 Ω peptide synthesizer (Aapptec, Louisville, USA) using standard 9-fluorenylmethoxycarbonyl (Fmoc) chemistry and Rink amide-MBHA resin (GL Biochem, Shanghai, China). Firstly, the Fmoc protected amino-acid attached to the resin was deprotected by 20% v/v piperidine in DMF. The subsequent amino acid protected by Fmoc at N-terminal was activated by HBTU in the presence of base NMM to form an acetic ester and was coupled to the C-terminal amino acid attached to the resin forming a dipeptide. Similarly, the remaining amino acids were coupled to form the complete sequence one by one. Finally, Fmoc groups was removed by incubating the resin twice with 20% v/v pyridine in DMF. The resin was washed in DMF four times before Fmoc removal and five times after Fmoc removal.

The crude peptides were deprotected and cleaved from the resin under reducing conditions by incubation in the cleavage solution (90% TFA, 2.5% H₂O, 2.5% thioanisole, 2.5% phenol, 2.5% EDT) with shaking for 4 h at room temperature. And then, they were isolated and purified by preparative high-performance liquid chromatography (Pre-HPLC, Agilent, Inc., USA). The final products were lyophilized for storing. The purity of the peptides was established by analytical HPLC (Agilent 1100, Agilent, Inc., USA), and the composition of the peptides was confirmed using a mass spectrometer (Bruker Daltonics micro TOF-Q, Hamburg, Germany). See the ESI† for more details (Fig. S8–S13).

Homogeneous time-resolved fluorescence (HTRF) binding assay

The binding activity of cyclic peptides towards the WBM site of WDR5 was tested by HTRF binding assay. The competitive substrate (RBBP5) peptide AAEEEDVDVTSVD with biotinylation at N-terminal and the positive control peptide SV-10 (SEEEIDVVSV) were synthesized by DongHeng Biopharm Co., Ltd. (Hangzhou, China). The WDR5 protein with His-sumo tag at N-terminal was aliquoted from storage. The fluorescent donor MAb anti-6His Tb and the fluorescent receptor streptavidin-d₂ used in the assay were purchased from Cisbio (PerkinElmer). The reaction was conducted with 20 μL final volume of terbium detection buffer (Cisbio) in an HTRF 96-well low volume plate (white). 5 μL of WDR5 protein at 20 nM and 5 μL of substrate peptide at 4 nM were mixed. 5 μL serially doubly diluted compound solution (SV-10, DH226027, CYC3, CYC4 and CYC7, final concentration from 500 μM to 976.6 nM) were followed. Finally, a 5 μL mixture of MAb anti-6His Tb and streptavidin-d₂ at a 1/100 dilution was added. After incubation at room temperature for 3 h, the plate was assayed on a Biotek Synergy Neo2 multi-mode microplate reader (excitation at 330 nm, emission at both 620 nm and 665 nm, Agilent). The measurement was conducted 3 times for reproducibility. The HTRF signal was calculated by signal ratio: [intensity (665 nm)/intensity (620 nm)] × 10⁴. The inhibition was calculated by the



following formula. The results were analyzed by GraphPad Prism software using a non-linear curve-fitting method.

$$(\text{inhibition})\% = \frac{S_{\text{max}} - S}{S_{\text{max}} - S_{\text{min}}} \times 100\%$$

S_{max} : the signal ratio of positive control without compounds; S_{min} : the signal ratio of negative control without protein; S : the signal ratio of each compound.

NMR spectroscopy

[^1H , ^{15}N] HSQC spectra of ^{15}N -labeled WDR5 with or without 10-fold molar excess of DH226027 were recorded on a Bruker 800 MHz NMR spectrometer equipped with a cryogenically cooled probe at 25 °C. The samples were prepared using a HEPES buffer containing 20 mM 2-[4-(2-hydroxyethyl) piperazin-1-yl] ethanesulfonic acid, 250 mM NaCl, 5 mM TCEP and 10% D_2O (pH 7.5), and the final concentration of WDR5 was 100 μM . The spectra were processed by using NMRPipe⁴⁰ and Sparky.⁴¹

Cyclization and purification of peptides with different chemical linkers

The chemical reagents were commercially available and used without further purification. The linear peptide DH226027-L was synthesized by DongHeng Biopharm Co., Ltd. (Hangzhou, China) as previously described. 10 mg lyophilized powder DH226027-L was dissolved in 8.5 mL methanol under the ultrasound conditions. Then, the cyclization linker (2 equiv.) and base triethylamine (3 equiv.) were added stepwise, and the mixture was stirred at 30 °C for 2 h. The reaction was quenched with 40% formic acid finally. Products were separated and purified with a C18 reversed-phase silica-gel column under methanol/water conditions. Fractions were collected and analyzed with an analytical HPLC system equipped with a C18 reversed-phase column (X-bridge peptide BEH C18 5 μm , 300 Å, 10 × 250 mm, Waters), applying a flow rate of 0.1 mL min^{-1} in 10 min and a mobile phase composed of solvent A (99.9% v/v H_2O and 0.1% v/v TFA) and solvent B (99.9% v/v ACN and 0.1% v/v TFA). The gradient elution condition is shown in Table S5.† The absorbance at a wavelength of 220 nm was used. The desired fractions were pooled, concentrated and successively lyophilized. In the end, the purity was assessed by analytical HPLC as previously mentioned, and the mass was determined by electrospray ionization mass spectrometry (ESI-MS) in positive ion mode on a single quadrupole liquid chromatography-mass spectrometer (Thermo Finnigan LCQ Deca XP LCMS-MS system, USA).

Stability experiments of cyclic peptides

The disulfide-bridged cyclic peptide DH226027 and the phenyl-bridged cyclic peptide CYC3 were chosen for the stability test. Additionally, in order to investigate the effects of pH values and reduction conditions of buffer solutions,

methanol buffers with TCEP at pH 3.0 and 7.4 were applied. The pH was measured using a Sartorius PB-10 basic benchtop pH meter equipped with a pH combination gel-filling electrode. Both powdered cyclic peptides were dissolved in two kinds of buffers that had been previously filtered through a 0.22 μm filter. The solutions were brought to a final volume of 2 mL, resulting in concentrations of 0.5 mM peptides and 1.0 mM TCEP. Then, the solutions were taken at different time points and analyzed using an analytical HPLC system.

Author contributions

The project was conceptualized by B. Xiong and D. Cao. Biopanning experiments were designed and performed by D. Cao and L. Song. Protein expression was completed by L. Song and Z. Du. Sequence analysis and binding assay were conducted by D. Cao and L. Song. NMR data were provided by N. Zhang. Chemical analysis and validation were interpreted by L. Song and L. Chen. The manuscript was written by B. Xiong, D. Cao and L. Song.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (82173658, 82373720).

References

- B. Sadikovic, K. Al-Romaih, J. A. Squire and M. Zielenska, *Curr. Genomics*, 2008, **9**, 394–408.
- T. C. S. Ho, A. H. Y. Chan and A. Ganesan, *J. Med. Chem.*, 2020, **63**, 12460–12484.
- J. P. Hu, C. Q. Tian, M. S. Damaneh, Y. L. Li, D. Y. Cao, K. K. Lv, T. Yu, T. Meng, D. Q. Chen, X. Wang, L. Chen, J. Li, S. S. Song, X. J. Huan, L. H. Qin, J. K. Shen, Y. Q. Wang, Z. H. Miao and B. Xiong, *J. Med. Chem.*, 2019, **62**, 8642–8663.
- N. Li, H. Yang, K. Liu, L. W. Zhou, Y. T. Huang, D. Y. Cao, Y. L. Li, Y. L. Sun, A. S. Yu, Z. Y. Du, F. Yu, Y. Zhang, B. Y. Wang, M. Y. Geng, J. Li, B. Xiong, S. L. Xu, X. Huang and T. C. Liu, *J. Med. Chem.*, 2022, **65**, 9459–9477.
- S. Valente, Y. W. Liu, M. Schneckeburger, C. Zwergel, S. Cosconati, C. Gros, M. Tardugno, D. Labella, C. Florean, S. Minden, H. Hashimoto, Y. Q. Chan, X. Zhang, G. Kirsch, E. Novellino, P. B. Arimondo, E. Miele, E. Ferretti, A. Gulino, M. Diederich, X. D. Cheng and A. Mai, *J. Med. Chem.*, 2014, **57**, 701–713.
- Z. Q. Zhang, Z. H. Guo, X. W. Xu, D. Y. Cao, H. Yang, Y. L. Li, Q. Y. Shi, Z. Y. Du, X. B. Guo, X. Wang, D. Q. Chen, Y. Zhang, L. Chen, K. X. Zhou, J. Li, M. Y. Geng, X. Huang and B. Xiong, *J. Med. Chem.*, 2021, **64**, 16650–16674.
- J. F. Couture, E. Collazo and R. C. Trievel, *Nat. Struct. Mol. Biol.*, 2006, **13**, 698–703.



- 8 J. H. Lee, C. M. Tate, J. S. You and D. G. Skalnik, *J. Biol. Chem.*, 2007, **282**, 13419–13428.
- 9 J. Dias, N. Van Nguyen, P. Georgiev, A. Gaub, J. Brettschneider, S. Cusack, J. Kadlec and A. Akhtar, *Genes Dev.*, 2014, **28**, 929–942.
- 10 L. S. Ee, K. N. McCannell, Y. Tang, N. Fernandes, W. R. Hardy, M. R. Green, F. Chu and T. G. Fazzio, *Stem Cell Rep.*, 2017, **8**, 1488–1496.
- 11 Y. L. Wang, F. Faiola, M. Xu, S. Pan and E. Martinez, *J. Biol. Chem.*, 2008, **283**, 33808–33815.
- 12 Y. W. Cho, T. Hong, S. Hong, H. Guo, H. Yu, D. Kim, T. Guszczynski, G. R. Dressler, T. D. Copeland, M. Kalkum and K. Ge, *J. Biol. Chem.*, 2007, **282**, 20395–20406.
- 13 X. Chen, J. Xu, X. Wang, G. Long, Q. You and X. Guo, *J. Med. Chem.*, 2021, **64**, 10537–10556.
- 14 Y. W. Yang, R. A. Flynn, Y. Chen, K. Qu, B. B. Wan, K. C. Wang, M. Lei and H. Y. Chang, *eLife*, 2014, **3**, e02046.
- 15 L. R. Thomas, Q. Wang, B. C. Grieb, J. Phan, A. M. Foshage, Q. Sun, E. T. Olejniczak, T. Clark, S. Dey, S. Lorey, B. Alicie, G. C. Howard, B. Cawthon, K. C. Ess, C. M. Eischen, Z. Zhao, S. W. Fesik and W. P. Tansey, *Mol. Cell*, 2015, **58**, 440–452.
- 16 S. Chacon Simon, F. Wang, L. R. Thomas, J. Phan, B. Zhao, E. T. Olejniczak, J. D. Macdonald, J. G. Shaw, C. Schlund, W. Payne, J. Creighton, S. R. Stauffer, A. G. Waterson, W. P. Tansey and S. W. Fesik, *J. Med. Chem.*, 2020, **63**, 4315–4333.
- 17 J. Tian, K. B. Teuscher, E. R. Aho, J. R. Alvarado, J. J. Mills, K. M. Meyers, R. D. Gogliotti, C. Han, J. D. Macdonald, J. Sai, J. G. Shaw, J. L. Sensintaffar, B. Zhao, T. A. Rietz, L. R. Thomas, W. G. Payne, W. J. Moore, G. M. Stott, J. Kondo, M. Inoue, R. J. Coffey, W. P. Tansey, S. R. Stauffer, T. Lee and S. W. Fesik, *J. Med. Chem.*, 2020, **63**, 656–675.
- 18 G. P. Smith, *Science*, 1985, **228**, 1315–1317.
- 19 J. Pande, M. M. Szewczyk and A. K. Grover, *Biotechnol. Adv.*, 2010, **28**, 849–858.
- 20 M. A. Abdalla and L. J. McGaw, *Molecules*, 2018, **23**, 2080.
- 21 A. Zorzi, K. Deyle and C. Heinis, *Curr. Opin. Chem. Biol.*, 2017, **38**, 24–29.
- 22 S. S. Usmani, G. Bedi, J. S. Samuel, S. Singh, S. Kalra, P. Kumar, A. A. Ahuja, M. Sharma, A. Gautam and G. P. S. Raghava, *PLoS One*, 2017, **12**, e0181748.
- 23 J. Cao, T. Fan, Y. Li, Z. Du, L. Chen, Y. Wang, X. Wang, J. Shen, X. Huang, B. Xiong and D. Cao, *Molecules*, 2021, **26**, 1225.
- 24 W. D. Thomas, M. Golomb and G. P. Smith, *Anal. Biochem.*, 2010, **407**, 237–240.
- 25 C. F. Barbas, J. S. Rosenblum and R. A. Lerner, *Proc. Natl. Acad. Sci. U. S. A.*, 1993, **90**, 6385–6389.
- 26 P. C. Weber, M. W. Pantoliano and L. D. Thompson, *Biochemistry*, 1992, **31**, 9350–9354.
- 27 M. Vodnik, U. Zager, B. Strukelj and M. Lunder, *Molecules*, 2011, **16**, 790–817.
- 28 J. Huang, B. Ru, S. Li, H. Lin and F. B. Guo, *J. Biomed. Biotechnol.*, 2010, **2010**, 101932.
- 29 G. Weng, J. Gao, Z. Wang, E. Wang, X. Hu, X. Yao, D. Cao and T. Hou, *J. Chem. Theory Comput.*, 2020, **16**, 3959–3969.
- 30 G. E. Mudd, A. Brown, L. Chen, K. van Rietschoten, S. Watcham, D. P. Teufel, S. Pavan, R. Lani, P. Huxley and G. S. Bennett, *J. Med. Chem.*, 2020, **63**, 4107–4116.
- 31 P. Diderich, D. Bertoldo, P. Dessen, M. M. Khan, I. Pizzitola, W. Held, J. Huelsken and C. Heinis, *ACS Chem. Biol.*, 2016, **11**, 1422–1427.
- 32 S. S. Kale, C. Villequey, X. D. Kong, A. Zorzi, K. Deyle and C. Heinis, *Nat. Chem.*, 2018, **10**, 715–723.
- 33 L. E. J. Smeenk, N. Dailly, H. Hiemstra, J. H. Van Maarseveen and P. Timmerman, *Org. Lett.*, 2012, **14**, 1194–1197.
- 34 P. Timmerman, J. Beld, W. C. Puijk and R. H. Meloen, *ChemBioChem*, 2005, **6**, 821–824.
- 35 Y. Wang and D. H.-C. Chou, *Angew. Chem., Int. Ed.*, 2015, **54**, 10931–10934.
- 36 N. Assem, D. J. Ferreira, D. W. Wolan and P. E. Dawson, *Angew. Chem., Int. Ed.*, 2015, **54**, 8665–8668.
- 37 M. E. B. Smith, F. F. Schumacher, C. P. Ryan, L. M. Tedaldi, D. Papaioannou, G. Waksman, S. Caddick and J. R. Baker, *J. Am. Chem. Soc.*, 2010, **132**, 1960–1965.
- 38 M. T. W. Lee, A. Maruani and V. Chudasama, *J. Chem. Res.*, 2016, 1–9, DOI: [10.3184/174751916x14495034614855](https://doi.org/10.3184/174751916x14495034614855).
- 39 G. A. Woolley, *Acc. Chem. Res.*, 2005, **38**, 486–493.
- 40 F. Delaglio, S. Grzesiek, G. W. Vuister, G. Zhu, J. Pfeifer and A. Bax, *J. Biomol. NMR*, 1995, **6**, 277–293.
- 41 D. G. Kneller and I. D. Kuntz, *J. Cell. Biochem.*, 1993, 254–254.

